Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
https://smallcaps.com.au/immuron-products-found-neutralise-covid-19-during-in-vitro-research/
Filter by Year:
- Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
- Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results
- Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment
- Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
- Immuron (ASX:IMC) develops research agreement
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
